IDP Pharma starts clinical trials of its first-in-class IDP-121 drug in hematological cancers and opens a financing round of €1M for the first phase of the study

by Parc Científic de Barcelona

The Spanish Agency of Medicines and Medical Devices has authorised the clinical trial of IDP-121, the first drug blocking and degrading a key oncoprotein in several hematological tumors, including mul...

Read more

Un ensayo clínico muestra la seguridad y eficacia del dispositivo de diálisis hepática DIALIVE en pacientes con insuficiencia hepática aguda sobre crónica, para quienes la única opción actual es el trasplante de hígado

by INCLIVA

Un ensayo clínico internacional controlado aleatorizado de Fase I, en humanos, utilizando DIALIVE -un novedoso dispositivo de diálisis hepática-, demostró su potencial como terapia modificadora de...

Read more

Novel platform shows preclinical and early clinical promise in accelerating the production of more effective CAR-T cell therapy

by VHIO

Researchers from VHIO's Experimental Hematology Group have participated in the development of a new technology to manufacture CAR-T cells or genetically modified lymphocytes to attack tumor cells, whi...

Read more

The CAR T-cell therapy from the Hospital Clínic-IDIBAPS for multiple myeloma is effective in patients with refractory disease

by Fundació Clínic per a la Recerca Biomèdica

A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients with multiple myeloma resistant to standard treatmen...

Read more

Positive aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

by Oryzon Genomics

Oryzon Genomics today reports new preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP).

Read more

Liquid biopsy in the policing and personalized treatment of GIST

by VHIO

Blood-based circulating tumor DNA analysis of plasma samples from patients enrolled in the open-label, randomized phase III VOYAGER clinical trial show that ctDNA sequencing can predict cancer drug re...

Read more

La Fundación 'la Caixa' y el hospital Clínic Barcelona renuevan su alianza de investigación contra el cáncer

by Fundació Clínic per a la Recerca Biomèdica

La Fundación ”la Caixa” destinará 4,6 millones de euros a potenciar la investigación en el hospital Clínic Barcelona con el objetivo de desarrollar nuevas terapias personalizadas para diversos...

Read more

New antiviral paves the way to HIV cure: less reservoir, inflammation and chronic immune system activation

by IrsiCaixa

The triple effect of obefazimod would make the drug a potential candidate when designing HIV remission strategies

Read more

La FDA aprueba la primera terapia génica para ciertos pacientes con distrofia muscular de Duchenne

by Revista Genética Médica

La Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) ha aprobado Elevidys, la primera terapia génica para el tratamiento de la distrofia muscular de Duche...

Read more

Development of new p38 protein inhibitors with therapeutic potential for some heart diseases

by IRB Barcelona - Instituto de Investigación Biomédica

A research team from IRB Barcelona and the biotech Nostrum Biodiscovery has developed a new type of inhibitor that blocks only some of the functions of the p38 protein. The alternative pathway that th...

Read more

A combination therapy, new option for patients with advanced urothelial cancer who cannot receive conventional chemotherapy

by Hospital de la Santa Creu i Sant Pau

Researcher has been able to verify that the combination of two drugs, enfortumab vedotin and pembrolizumab, which had previously shown benefits in survival in second-line treatment and in cases of adv...

Read more

Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)

by Ysios Capital

Mineralys Therapeutics today announced details of an expanded two-part Phase 2 clinical trial for lorundrostat as a potential therapy to treat patients with Stage 2 to 4 chronic kidney disease (CKD), ...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un ensayo de microscopía dinámica del ...

by CSIC - Centro Superior de Investigaciones Científicas

La revista ‘Nature Protocols’ selecciona esta técnica como “pro...

Photos Stream